BACKGROUND: Trastuzumab has shown a survival benefit in cases of Her2-positive gastroesophageal cancer (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for trastuzumab-based therapy. However, these low-throughput assays often produce discordant or equivocal results. METHODS: We developed a targeted proteomic assay based on selected reaction monitoring mass spectrometry (SRM-MS) and quantified levels (amol/μg) of Her2-SRM protein in cell lines (n = 27) and GEC tissues (n = 139). We compared Her2-SRM protein expression with IHC/FISH, seeking to determine optimal SRM protein expression cutoffs in order to identify HER2 gene amplification. RESULTS: After demonstrating assay development, precision, and stability, Her2-SRM protein measurement was observed to be highly concordant with the HER2/CEP17 ratio, particularly in a multivariate regression model adjusted for SRM expression of the covariates Met, Egfr, Her3, and HER2 heterogeneity, as well as their interactions (cell lines r (2) = 0.9842; FFPE r (2) = 0.7643). In GEC tissues, Her2-SRM protein was detected at any level in 71.2 % of cases. ROC curves demonstrated that Her2-SRM protein levels have a high specificity (100 %) at an upper-level cutoff of >750 amol/µg and sensitivity of 75 % at a lower-level cutoff of <450 amol/μg for identifying HER2 FISH-amplified tumors. An "equivocal zone" of 450-750 amol/µg of Her2-SRM protein was analogous to IHC2+ but represented fewer cases (9-16 % of cases versus 36-41 %). CONCLUSIONS: Compared to IHC, targeted SRM-Her2 proteomics provided more objective and quantitative Her2 expression with excellent HER2/CEP17 FISH correlation and fewer equivocal cases. Along with its multiplex capability for other relevant oncoproteins, these results demonstrate a refined HER2 protein expression assay for clinical application.
BACKGROUND:Trastuzumab has shown a survival benefit in cases of Her2-positive gastroesophageal cancer (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for trastuzumab-based therapy. However, these low-throughput assays often produce discordant or equivocal results. METHODS: We developed a targeted proteomic assay based on selected reaction monitoring mass spectrometry (SRM-MS) and quantified levels (amol/μg) of Her2-SRM protein in cell lines (n = 27) and GEC tissues (n = 139). We compared Her2-SRM protein expression with IHC/FISH, seeking to determine optimal SRM protein expression cutoffs in order to identify HER2 gene amplification. RESULTS: After demonstrating assay development, precision, and stability, Her2-SRM protein measurement was observed to be highly concordant with the HER2/CEP17 ratio, particularly in a multivariate regression model adjusted for SRM expression of the covariates Met, Egfr, Her3, and HER2 heterogeneity, as well as their interactions (cell lines r (2) = 0.9842; FFPE r (2) = 0.7643). In GEC tissues, Her2-SRM protein was detected at any level in 71.2 % of cases. ROC curves demonstrated that Her2-SRM protein levels have a high specificity (100 %) at an upper-level cutoff of >750 amol/µg and sensitivity of 75 % at a lower-level cutoff of <450 amol/μg for identifying HER2 FISH-amplified tumors. An "equivocal zone" of 450-750 amol/µg of Her2-SRM protein was analogous to IHC2+ but represented fewer cases (9-16 % of cases versus 36-41 %). CONCLUSIONS: Compared to IHC, targeted SRM-Her2 proteomics provided more objective and quantitative Her2 expression with excellent HER2/CEP17 FISH correlation and fewer equivocal cases. Along with its multiplex capability for other relevant oncoproteins, these results demonstrate a refined HER2 protein expression assay for clinical application.
Entities:
Keywords:
Clinical biomarker assay; Companion diagnostic; Esophageal; Gastric; Gastroesophageal adenocarcinoma; HER2 (ERBB2) amplification; Her2 expression; Multiplex protein expression analysis in FFPE tissue; SRM-MS; Selected reaction monitoring mass spectrometry; Stomach cancer
Authors: Terri A Addona; Susan E Abbatiello; Birgit Schilling; Steven J Skates; D R Mani; David M Bunk; Clifford H Spiegelman; Lisa J Zimmerman; Amy-Joan L Ham; Hasmik Keshishian; Steven C Hall; Simon Allen; Ronald K Blackman; Christoph H Borchers; Charles Buck; Helene L Cardasis; Michael P Cusack; Nathan G Dodder; Bradford W Gibson; Jason M Held; Tara Hiltke; Angela Jackson; Eric B Johansen; Christopher R Kinsinger; Jing Li; Mehdi Mesri; Thomas A Neubert; Richard K Niles; Trenton C Pulsipher; David Ransohoff; Henry Rodriguez; Paul A Rudnick; Derek Smith; David L Tabb; Tony J Tegeler; Asokan M Variyath; Lorenzo J Vega-Montoto; Asa Wahlander; Sofia Waldemarson; Mu Wang; Jeffrey R Whiteaker; Lei Zhao; N Leigh Anderson; Susan J Fisher; Daniel C Liebler; Amanda G Paulovich; Fred E Regnier; Paul Tempst; Steven A Carr Journal: Nat Biotechnol Date: 2009-06-28 Impact factor: 54.908
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Angela N Bartley; Jessi Christ; Patrick L Fitzgibbons; Stanley R Hamilton; Sanjay Kakar; Manish A Shah; Laura H Tang; Megan L Troxell Journal: Arch Pathol Lab Med Date: 2014-10-02 Impact factor: 5.534
Authors: J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Todd Hembrough; Sheeno Thyparambil; Wei-Li Liao; Marlene M Darfler; Joseph Abdo; Kathleen M Bengali; Stephen M Hewitt; Richard A Bender; David B Krizman; Jon Burrows Journal: J Mol Diagn Date: 2013-05-11 Impact factor: 5.568
Authors: Harry H Yoon; Qian Shi; William R Sukov; Mark A Lewis; Christopher A Sattler; Anne E Wiktor; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: Daniel V T Catenacci; Wei-Li Liao; Sheeno Thyparambil; Les Henderson; Peng Xu; Lei Zhao; Brittany Rambo; John Hart; Shu-Yuan Xiao; Kathleen Bengali; Jamar Uzzell; Marlene Darfler; David B Krizman; Fabiola Cecchi; Donald P Bottaro; Theodore Karrison; Timothy D Veenstra; Todd Hembrough; Jon Burrows Journal: PLoS One Date: 2014-07-01 Impact factor: 3.240
Authors: Steven B Maron; Leah M Chase; Samantha Lomnicki; Sara Kochanny; Kelly L Moore; Smita S Joshi; Stacie Landron; Julie Johnson; Lesli A Kiedrowski; Rebecca J Nagy; Richard B Lanman; Seung Tae Kim; Jeeyun Lee; Daniel V T Catenacci Journal: Clin Cancer Res Date: 2019-08-19 Impact factor: 12.531
Authors: Jorge A Carrasquillo; Maurizio Scaltriti; Nikolaus Schultz; Yelena Y Janjigian; Francisco Sanchez-Vega; Jaclyn F Hechtman; Pau Castel; Geoffrey Y Ku; Yaelle Tuvy; Helen Won; Christopher J Fong; Nancy Bouvier; Gouri J Nanjangud; Joanne Soong; Efsevia Vakiani; Mark Schattner; David P Kelsen; Robert A Lefkowitz; Karen Brown; Mario E Lacouture; Marinela Capanu; Marissa Mattar; Besnik Qeriqi; Fabiola Cecchi; Yuan Tian; Todd Hembrough; Rebecca J Nagy; Richard B Lanman; Steven M Larson; Neeta Pandit-Taskar; Heiko Schöder; Christine A Iacobuzio-Donahue; David H Ilson; Wolfgang A Weber; Michael F Berger; Elisa de Stanchina; Barry S Taylor; Jason S Lewis; David B Solit Journal: Cancer Discov Date: 2018-11-21 Impact factor: 39.397
Authors: Steven B Maron; Lindsay Alpert; Heewon A Kwak; Samantha Lomnicki; Leah Chase; David Xu; Emily O'Day; Rebecca J Nagy; Richard B Lanman; Fabiola Cecchi; Todd Hembrough; Alexa Schrock; John Hart; Shu-Yuan Xiao; Namrata Setia; Daniel V T Catenacci Journal: Cancer Discov Date: 2018-02-15 Impact factor: 39.397
Authors: Daniel V T Catenacci; Stephanie Moya; Samantha Lomnicki; Leah M Chase; Bryan F Peterson; Natalie Reizine; Lindsay Alpert; Namrata Setia; Shu-Yuan Xiao; John Hart; Uzma D Siddiqui; D Kyle Hogarth; Oliver S Eng; Kiran Turaga; Kevin Roggin; Mitchell C Posner; Paul Chang; Sunil Narula; Murtuza Rampurwala; Yuan Ji; Theodore Karrison; Chih-Yi Liao; Blase N Polite; Hedy L Kindler Journal: Cancer Discov Date: 2020-11-24 Impact factor: 39.397
Authors: E An; C-Y Ock; T-Y Kim; K-H Lee; S-W Han; S-A Im; T-Y Kim; W-L Liao; F Cecchi; A Blackler; S Thyparambil; W H Kim; J Burrows; T Hembrough; D V T Catenacci; D-Y Oh; Y-J Bang Journal: Ann Oncol Date: 2017-01-01 Impact factor: 32.976